Senior Group Leader

Research Group Home Page: 
Brenton Group

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

E-pub date: 28 Feb 2019


Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference.

E-pub date: 28 Feb 2019


Shared heritability and functional enrichment across six solid cancers.

E-pub date: 31 Dec 2018


Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk.

E-pub date: 30 Nov 2018


Enhanced detection of circulating tumor DNA by fragment size analysis.

E-pub date: 31 Oct 2018


BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

E-pub date: 31 Oct 2018


Personalising Treatment for High-Grade Serous Ovarian Carcinoma.

E-pub date: 31 Aug 2018


Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

E-pub date: 01 Aug 2018


Copy number signatures and mutational processes in ovarian carcinoma.

E-pub date: 31 Jul 2018


Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients.

E-pub date: 31 Jul 2018


You won’t believe this old test … that does cheap single-cell mutation detection.

E-pub date: 01 Jul 2018


A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.

E-pub date: 30 Jun 2018


Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

E-pub date: 30 Jun 2018


Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.

E-pub date: 23 Apr 2018


Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.

E-pub date: 31 Mar 2018


Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

E-pub date: 31 Mar 2018


MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

E-pub date: 31 Mar 2018


Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.

E-pub date: 31 Dec 2017


Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

E-pub date: 01 Dec 2017


Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

E-pub date: 01 Nov 2017


Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.

E-pub date: 20 Sep 2017


Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

E-pub date: 01 Aug 2017


Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

E-pub date: 31 May 2017


Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

E-pub date: 09 May 2017


Liquid biopsies come of age: towards implementation of circulating tumour DNA.

E-pub date: 01 Apr 2017


Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.

E-pub date: 03 Mar 2017


CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.

E-pub date: 17 Feb 2017


Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging.

E-pub date: 31 Jan 2017


Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

E-pub date: 31 Jan 2017


Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer.

E-pub date: 09 Jan 2017


Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.

E-pub date: 31 Dec 2016


New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study.

E-pub date: 31 Oct 2016


Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

E-pub date: 31 Oct 2016


Sequencing Structural Variants in Cancer for Precision Therapeutics.

E-pub date: 01 Sep 2016


Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1β (HNF1β) transcription factor is imported into the nucleus via a monopartite NLS sequence.

E-pub date: 01 Sep 2016


SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

E-pub date: 31 Aug 2016


Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.

E-pub date: 26 May 2016


Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

E-pub date: 31 Mar 2016


Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples.

E-pub date: 31 Mar 2016


Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

E-pub date: 16 Feb 2016


Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma.

E-pub date: 31 Jan 2016


Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

E-pub date: 01 Nov 2015


A Bayesian adaptive design for biomarker trials with linked treatments.

E-pub date: 01 Sep 2015


Molecular pathogenesis of ovarian clear cell carcinoma.

E-pub date: 31 Aug 2015


Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

E-pub date: 31 Jul 2015


Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

E-pub date: 01 Apr 2015


Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.

E-pub date: 01 Feb 2015


Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.

E-pub date: 01 Feb 2015


A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

E-pub date: 31 Jan 2015


Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.

E-pub date: 17 Dec 2014


Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

E-pub date: 09 Dec 2014


Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists.

E-pub date: 29 Nov 2014


883PDPRELIMINARY RESULTS OF ARIEL2, A PHASE 2 OPEN-LABEL STUDY TO IDENTIFY OVARIAN CANCER PATIENTS LIKELY TO RESPOND TO RUCAPARIB.

E-pub date: 01 Sep 2014


Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women.

E-pub date: 31 Aug 2014


Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

E-pub date: 31 Aug 2014


Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.

E-pub date: 15 May 2014


Phylogenetic quantification of intra-tumour heterogeneity.

E-pub date: 01 Apr 2014


Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

E-pub date: 31 Aug 2013


The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling.

E-pub date: 01 Jul 2013


Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

E-pub date: 02 May 2013


A metadata-aware application for remote scoring and exchange of tissue microarray images.

E-pub date: 01 May 2013


GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.

E-pub date: 01 Apr 2013


Stem cells: Anatomy of an ovarian cancer.

E-pub date: 14 Mar 2013


Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.

E-pub date: 19 Feb 2013


Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

E-pub date: 22 Dec 2012


Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.

E-pub date: 29 Nov 2012


Complex stiffness gradient substrates for studying mechanotactic cell migration.

E-pub date: 27 Nov 2012


Complex stiffness gradient substrates for studying mechanotactic cell migration (adv. Mater. 45/2012).

E-pub date: 27 Nov 2012


Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.

E-pub date: 31 Aug 2012


Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.

E-pub date: 31 Aug 2012


Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

E-pub date: 30 May 2012


ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

E-pub date: 28 May 2012


The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

E-pub date: 18 Apr 2012


Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects.

E-pub date: 01 Apr 2012


The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.

E-pub date: 01 Apr 2012


A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles.

E-pub date: 08 Mar 2012


Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1.

E-pub date: 01 Mar 2012


Evolution of platinum resistance in high-grade serous ovarian cancer.

E-pub date: 01 Nov 2011


Ovarian clear cell carcinoma–bad endometriosis or bad endometrium?

E-pub date: 31 Oct 2011


Rethinking ovarian cancer: recommendations for improving outcomes.

E-pub date: 23 Sep 2011


High fragmentation characterizes tumour-derived circulating DNA.

E-pub date: 31 Aug 2011


Two novel determinants of etoposide resistance in small cell lung cancer.

E-pub date: 15 Jul 2011


Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression.

E-pub date: 01 Apr 2011


Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.

E-pub date: 18 Jan 2011


Total syntheses of subereamollines A and B.

E-pub date: 07 Jan 2011


Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer.

E-pub date: 23 Nov 2010


Slingshot: a PiggyBac based transposon system for tamoxifen-inducible ‘self-inactivating’ insertional mutagenesis.

E-pub date: 31 Oct 2010


Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.

E-pub date: 02 Sep 2010


Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer.

E-pub date: 31 Aug 2010


PathGrid: a service-orientated architecture for microscopy image analysis.

E-pub date: 28 Aug 2010


Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.

E-pub date: 31 Jul 2010


Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

E-pub date: 31 May 2010


Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease.

E-pub date: 01 Apr 2010


Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development.

E-pub date: 01 Feb 2010


The pitfalls of platform comparison: DNA copy number array technologies assessed.

E-pub date: 08 Dec 2009


A metadata approach for clinical data management in translational genomics studies in breast cancer.

E-pub date: 30 Nov 2009


The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.

E-pub date: 24 Nov 2009


Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T.

E-pub date: 31 Oct 2009


Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.

E-pub date: 01 Jul 2009


Mutation of FOXL2 in granulosa-cell tumors of the ovary.

E-pub date: 25 Jun 2009


One-stop diagnostic breast clinics: how often are breast cancers missed?

E-pub date: 16 Jun 2009


Chromosomal instability determines taxane response.

E-pub date: 26 May 2009


Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?

E-pub date: 31 Jan 2009


Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.

E-pub date: 01 Sep 2008


Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.

E-pub date: 31 Aug 2008


The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.

E-pub date: 31 Dec 2007


High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

E-pub date: 31 Aug 2007


High resolution melting for mutation scanning of TP53 exons 5-8.

E-pub date: 31 Aug 2007


BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines.

E-pub date: 15 Jul 2007


Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

E-pub date: 01 Jun 2007


Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

E-pub date: 22 Mar 2007


A gene-expression signature to predict survival in breast cancer across independent data sets.

E-pub date: 01 Mar 2007


Proposed methods for testing and selecting the ERCC external RNA controls.

E-pub date: 31 Oct 2005


A silencer element identified in Drosophila is required for imprinting of H19 reporter transgenes in mice.

E-pub date: 31 Jul 1999


Show all
Research Integrity Conflict of Interest Disclosure: 
Last revised: 
12/01/2019
Company Active Research funding Ownership Royalty payments Commitment to carry out work for a fee Ad hoc reimbursed work Travel Gifts/ other
Inivata Ltd Yes No No No Yes No No No
Astra Zeneca Yes Yes No No No Yes No No
Clovis Oncology Yes Yes No No No No No No
Aprea Yes Yes No No No No No No
Bayer Yes No No No No Yes No No
SCOR Yes No No No Yes No No No
PartnerRe Yes No No No Yes No No No
Greycastle Services Ltd Yes No No No Yes No No No
Pacific Life Re Yes No No No Yes No No No
Disclosure guidelines